Background/Objectives: The PHASES score is widely used to estimate the 5-year rupture risk of unruptured intracranial aneurysms, yet many patients present with aneurysmal subarachnoid haemorrhage despite low calculated risk. This study aimed to characterise the demographic and aneurysm-related profile of patients with ruptured aneurysms classified as low risk by PHASES. Methods: This retrospective single-centre observational study included 243 consecutive patients with radiologically confirmed ruptured intracranial aneurysms treated between 2013 and 2021. PHASES scores and estimated 5-year rupture risks were calculated retrospectively. Age, sex, arterial hypertension, aneurysm size, location, and multiplicity were analysed using non-parametric statistical methods. Results: The mean PHASES score was 5.16 +/- 3.43 points. An estimated 5-year rupture risk below 1% was assigned to 125 patients (51.44%), and 54 patients (22.22%) had PHASES scores of 0-2. Ruptured aneurysms measuring <= 7 mm occurred in 147 patients (60.49%), and 210 patients (86.42%) were younger than 70 years. Internal carotid artery aneurysms were the most frequent overall, whereas anterior communicating artery aneurysms had the smallest median diameter while remaining among the most common rupture sites. Arterial hypertension was associated with larger aneurysm diameter. Conclusions: Low PHASES-estimated risks were common in this cohort of patients presenting with aneurysm rupture. Because the study included no comparison group with unruptured aneurysms, it cannot assess PHASES calibration or predictive performance. PHASES should therefore be used as a population-based decision-support tool rather than a stand-alone predictor of individual rupture risk, with morphology, imaging findings, documented growth, and patient-specific factors incorporated into clinical assessment.
e16579 Background: Neoadjuvant chemotherapy (NACT) in patients (pts) with muscle-invasive bladder cancer (MIBC) significantly improves treatment outcomes. Widely used NACT regimen based on 3-4 cycles of gemcitabine and cisplatin (GC) before radical cystectomy (RC) remained the standard of care until the complete results of the VESPER trial, which demonstrated the superiority of 6 cycles of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) in terms of progression-free survival (PFS), complete pathological responses (pCR) and overall survival (OS). In most clinical trials, pts with clinically positive lymph nodes (N+ according to TMN) were underrepresented. The aim of the study is to compare the effectiveness and safety of the mentioned NACT regimens in real medical practice. Methods: Pts from 7 urooncology hospitals in Poland with MIBC stage ≥T2, cM0 treated with NACT GC or ddMVAC (11/2016-09/2024) were included. Pts from clinical trials were excluded. Complete clinical data were collected. Survival analyses were performed using the Kaplan-Meier method, Log-rank and chi-square or Fisher's tests were used for comparison between groups. Data cut-off was 31/12/2024. Results: Of the 261 pts treated with NACT, 232 were included in the analysis: 132 (57%) received GC, 100 (43%) ddMVAC). There were 55 (24%) women in the study groups, the median age was 67, cT2N0: 90 (39%), N+: 61 (27%), baseline anemia of any grade: 107 (48%). In the GC group, there were significantly more ECOG performance status (PS) 2 pts, p=0.0076, other variables did not differ significantly. Median total dose of cisplatin (MTDC) was significantly higher in ddMVAC group than in GC group (280 vs 210 mg/m2), p=0.0024. Median chemotherapy period was significantly longer in GC pts: 9 vs 6.3 weeks for ddMVAC, p=0.0007. RC was not performed in 35 (15%) of pts due to adverse events (AEs), progression, or withdrawal of consent. More objective pathological responses were achieved in the ddMVAC vs GC pts, 42 vs 14%, p<0,0001, however, there were no differences in clinical response. Significant difference in mOS between GP and ddMVAC group was observed: 27 vs 39m, p=0.0203. In univariate analysis, a significant advantage was also observed for MTDC ≥250mg/m2, p=0.0093; ECOG PS 0, p=0.0018; RC, p=0.01; R0 resection, p=0.001; and pCR, p<0.0001 in terms of OS. OS did not differ significantly between cT2N0 or >cT2N0 pts, p=0.3. Multivariate analysis confirmed a statistically significant OS benefit for ECOG PS 0, higher MDTC and pCR. More hematological AEs occured in the GC vs ddMVAC group: 98% vs 84%, p=0.0007. Conclusions: The use of NACT with the ddMVAC in MIBC pts showed a statistically significant improvement of OS compared to GC with favorable toxicity. The study indicates that the best prognosis is for pts with ECOG PS 0 who received a higher MTDC (preferably in the ddMVAC regimen), responded to NACT and underwent radical surgery regardless of the primary clinical stage of T and N.
Introduction: Cryotherapy, encompassing whole-body cryotherapy (WBC) and partial-body cryotherapy (PBC), has gained increasing attention in sports, medicine, rehabilitation, and wellness for its potential anti-inflammatory, analgesic, and recovery-enhancing effects. Originally developed in Japan in the late 1970s for the treatment of rheumatoid arthritis, WBC has since evolved into a multidisciplinary therapeutic modality with a wide range of clinical and non-clinical applications. Materials and Methods: A systematic literature search of PubMed and Embase from 2013–2025 was conducted using the terms “cryotherapy,” “whole-body cryotherapy,” and “cryostimulation.” Results: The evidence suggests that WBC elicits systemic anti-inflammatory effects through modulation of cytokines (e.g., decreased IL-1β, TNF-α, and hsCRP; increased IL-10), enhances antioxidant enzyme activity, and improves markers of oxidative stress. Clinical data further indicate beneficial outcomes in conditions such as rheumatic and osteoarticular diseases, fibromyalgia, multiple sclerosis, mood disorders, chronic pain, and obesity. WBC may also support athletic recovery by reducing muscle soreness and improving performance adaptation. Despite its broad therapeutic potential, contraindications, including cardiovascular, neurological, and cold-related disorders, must be observed. Reported adverse effects are generally mild and transient. Conclusions: Overall, cryotherapy appears to be a promising adjunctive modality, though further controlled studies are warranted to establish standardised treatment protocols and confirm long-term safety and efficacy.
e21575 Background: The treatment of early-stage melanoma is rapidly changing. Recent advancements include neoadjuvant treatment in stage III clinically detected disease and adjuvant treatment in stage IIB/C melanoma. In particular, adjuvant immunotherapy for IIB/C disease has become recently available. We took this opportunity to evaluate changes in outcomes in patients diagnosed with stage II and III melanoma. Methods: We have analyzed the accessible, retrospective data on patients diagnosed with melanoma between 2015 and 2022 who underwent sentinel lymph node biopsy or therapeutic lymph node dissection in high-throughput centers in Poland. The data on primary staging, patients’ demographics, and information on follow-up and overall survival (OS) were collected. A prespecified OS Cox model with non-linear terms for age, sex, stage (II vs. III), and availability of adjuvant treatment in stage III (i.e., since 2021) was fitted. Results: There were 1970 patients (45.2% female) included in this analysis. The mean age was 62 (range:14-97). The exact stage distribution and 3-year OS rates are presented in Table 1. Patients diagnosed with stage III melanoma before 2021 had worse prognoses than stage II patients (HR: 1.33, 95%CI: 1.11-1.60, p=0.002). Since then the prognosis for stage II patients did not improve (HR: 1.13, 95%CI: 0.89-1.45, p=0.325) while the prognosis in stage III melanoma became similar to stage II after the introduction of adjuvant therapy (HR: 1.09, 95% CI: 0.78-1.53, p = 0.607). Conclusions: The introduction of adjuvant treatment improved the OS of stage III melanoma patients in this nationwide study. The modern prognosis is similar to patients with stage II melanoma without adjuvant treatment, with excellent results in stage IIIA/IIIB cases. The practitioners should be cautious when discussing historical prognosis with their patients and it implies the necessity of changes in AJCC staging. Stage distribution and 3-year survival rates. Stage Number of patients Percentage of group 3 year survial rate (%) 95% Confidence Interval (%) IIA 352 17.9 86.5 82.9 - 90.3 IIB 378 19.2 76.5 72.2 - 81.2 IIC 443 22.5 59.9 55.3 - 64.8 IIIA 84 4.3 94.3 89.1 - 99.9 IIIB 132 6.7 94.6 90.5 - 98.9 IIIC 518 26.3 68.5 64.3 - 73.1 IIID 63 3.2 53.3 42.2 - 67.4